These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 27409838

  • 1. Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.
    Gasca J, Flores ML, Giráldez S, Ruiz-Borrego M, Tortolero M, Romero F, Japón MA, Sáez C.
    Oncotarget; 2016 Aug 16; 7(33):52751-52765. PubMed ID: 27409838
    [Abstract] [Full Text] [Related]

  • 2. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
    Spänkuch B, Kurunci-Csacsko E, Kaufmann M, Strebhardt K.
    Oncogene; 2007 Aug 23; 26(39):5793-807. PubMed ID: 17369857
    [Abstract] [Full Text] [Related]

  • 3. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
    Spänkuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kaufmann M, Strebhardt K.
    Cancer Res; 2006 Jun 01; 66(11):5836-46. PubMed ID: 16740723
    [Abstract] [Full Text] [Related]

  • 4. FBXW7 mediates chemotherapeutic sensitivity and prognosis in NSCLCs.
    Yokobori T, Yokoyama Y, Mogi A, Endoh H, Altan B, Kosaka T, Yamaki E, Yajima T, Tomizawa K, Azuma Y, Onozato R, Miyazaki T, Tanaka S, Kuwano H.
    Mol Cancer Res; 2014 Jan 01; 12(1):32-7. PubMed ID: 24165483
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to paclitaxel.
    Zhao W, Song Y, Xu B, Zhan Q.
    Cancer Biol Ther; 2012 Feb 01; 13(3):156-63. PubMed ID: 22353935
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
    Torres-Adorno AM, Lee J, Kogawa T, Ordentlich P, Tripathy D, Lim B, Ueno NT.
    Clin Cancer Res; 2017 Aug 15; 23(16):4780-4792. PubMed ID: 28465444
    [Abstract] [Full Text] [Related]

  • 15. The FBXW7-NOTCH interactome: A ubiquitin proteasomal system-induced crosstalk modulating oncogenic transformation in human tissues.
    Kar R, Jha SK, Ojha S, Sharma A, Dholpuria S, Raju VSR, Prasher P, Chellappan DK, Gupta G, Kumar Singh S, Paudel KR, Hansbro PM, Kumar Singh S, Ruokolainen J, Kesari KK, Dua K, Jha NK.
    Cancer Rep (Hoboken); 2021 Aug 15; 4(4):e1369. PubMed ID: 33822486
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The FBXW7 tumor suppressor inhibits breast cancer proliferation and promotes apoptosis by targeting MTDH for degradation.
    Chen X, Li XY, Long M, Wang X, Gao ZW, Cui Y, Ren J, Zhang Z, Liu C, Dong K, Zhang H.
    Neoplasma; 2018 Aug 15; 65(2):201-209. PubMed ID: 29534580
    [Abstract] [Full Text] [Related]

  • 18. FBXW7 tumor suppressor regulation by dualspecificity tyrosine-regulated kinase 2.
    Jiménez-Izquierdo R, Morrugares R, Suanes-Cobos L, Correa-Sáez A, Garrido-Rodríguez M, Cerero-Tejero L, Khan OM, de la Luna S, Sancho R, Calzado MA.
    Cell Death Dis; 2023 Mar 18; 14(3):202. PubMed ID: 36934104
    [Abstract] [Full Text] [Related]

  • 19. MAGEA1 interacts with FBXW7 and regulates ubiquitin ligase-mediated turnover of NICD1 in breast and ovarian cancer cells.
    Zhao J, Wang Y, Mu C, Xu Y, Sang J.
    Oncogene; 2017 Aug 31; 36(35):5023-5034. PubMed ID: 28459460
    [Abstract] [Full Text] [Related]

  • 20. Circadian Clock Gene CRY2 Degradation Is Involved in Chemoresistance of Colorectal Cancer.
    Fang L, Yang Z, Zhou J, Tung JY, Hsiao CD, Wang L, Deng Y, Wang P, Wang J, Lee MH.
    Mol Cancer Ther; 2015 Jun 31; 14(6):1476-87. PubMed ID: 25855785
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.